New Cousteau-Linked...
Health Care: Drugs
ADVENTRX Pharmaceuticals Inc. (ANX: AMEX)
$0.51 -0.01 | -2.11%
06/04/12 - 03:14 PM ET
Company Cash Flow
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -13.26M | -8.45M | -11.33M | -26.65M |
| Operating Gains/Losses | -1.46M | 4.27K | 59.11K | -3.60K |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | 196.53K | -552.21K | -2.36M | 1.22M |
| (Decrease) Increase In Other Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Working Capital | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Cash Items | 866.05K | 785.94K | 585.44K | 1.39M |
| Net Cash From Continuing Operations | -13.47M | -8.34M | -12.62M | -23.79M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -13.47M | -8.34M | -12.62M | -23.79M |
| Sale of Property, Plant & Equipment | 12.64K | 4.38K | 16.00K | 33.91K |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 0.00 | 33.24M |
| Purchases of Property, Plant & Equipment | -411.76K | -28.51K | 0.00 | -64.96K |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | -7.14M | 0.00 | 0.00 | -14.36M |
| Other Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -7.54M | -24.13K | 16.00K | 18.86M |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 39.51M | 30.77M | 12.83M | 0.00 |
| Repayment of Long-Term Debt | 0.00 | 0.00 | -1.42M | 0.00 |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | -2.90M | -3.09M | 0.00 | 0.00 |
| Net Cash From Financing Activities | 36.60M | 27.68M | 11.42M | 0.00 |
| Effect of Exchange Rate Changes | -2.16K | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | 15.59M | 19.31M | -1.18M | -4.93M |
Portfolios with ANX
- Portfolio NameUser Type
- Uservlady 1
- Usertesting
- Contributor5 Stocks Under-$10 Setting ...
- ContributorBreakout Stocks Of The Week...
- ContributorHot Biotech Trades for Seco...
- UserDusty's Tracker
- UserDustel's Growth Stocks
- UserOwn
- UserASCO 2010 Part 2
- UserCDBrevard Portfolio 1
Latest ANX Headlines from TheStreet
- For Biotech, 'Fail' is Making a Big Comeback 03.12.12 | 08:03 am
- ADVENTRX Stock Gaps Down On Today's Open (ANX) 11.11.11 | 08:11 am
- 5 Stocks Under $10 Setting Up to Trade Higher 09.15.11 | 01:09 pm
- 5 Stocks Setting Up to Break Out 09.09.11 | 03:09 pm
- ADVENTRX Stock Hits New 52-Week Low (ANX) 08.10.11 | 09:08 am
- Adventrx: FDA Rejects Lung Cancer Drug 08.10.11 | 07:08 am
- ADVENTRX Stock Gaps Down On Today's Open (ANX) 08.08.11 | 10:08 am
- Biotech Stock Mailbag: Sangamo Biosciences 07.22.11 | 05:07 am
- Biotech Stock Live Chat 07.15.11 | 12:07 pm
- Biotech Stock Mailbag: Adventrx Pharma 07.15.11 | 05:07 am
Press Releases for ANX
- ADVENTRX Pharmaceuticals To Sponsor & Present At The Martin Center's 2012 Sickle Cell Disease Conference - PR Newswire 04.16.12 | 08:04 am
- ADVENTRX Announces Establishment Of Regulatory Advisory Board - PR Newswire 04.09.12 | 08:04 am
- Vista Partners Updates Coverage On ADVENTRX Pharmaceuticals, Inc.; $3.50 Target Price - PR Newswire 03.21.12 | 09:03 am
- ADVENTRX CEO Selected By Combined Health Agencies As A 2012 Health Hero - PR Newswire 03.15.12 | 08:03 am
- ADVENTRX Pharmaceuticals To Present At The 14th Annual BIO CEO & Investor Conference On February 14 - PR Newswire 02.07.12 | 08:02 am
- Vista Partners Publishes February 2012 Newsletter - PR Newswire 02.02.12 | 09:02 am
- Vista Partners Updates Coverage On ADVENTRX Pharmaceuticals, Inc.; $3.50 Target Price - PR Newswire 12.15.11 | 09:12 am
- ADVENTRX Meets With FDA To Discuss Development Plans For ANX-188 - PR Newswire 12.01.11 | 08:12 am
- ADVENTRX Announces Closing Of Public Offering - PR Newswire 11.16.11 | 03:11 pm
- ADVENTRX Prices Public Offering Of Stock - PR Newswire 11.11.11 | 08:11 am
Partner Headlines for ANX
- Zacks #1 Rank Additions for Monday - Tale of the Tape - Zacks 12.19.11 | 09:12 am
- Why CytRx Corporation Is Still A Big Biotech 'If' Play - Seeking Alpha 12.14.11 | 09:12 am
- Blue Horseshoe - Or Someone - Likes Anaconda Mining; Shares Pop 20% After Selling Iron Ore Assets - NASDAQ 12.07.11 | 06:12 pm
- Zacks #1 Rank Additions for Friday - Tale of the Tape - Zacks 12.02.11 | 09:12 am
- 5 Healthcare Stocks To Consider - Seeking Alpha 09.01.11 | 08:09 am
- Company News for August 11, 2011 - Corporate Summary - Zacks 08.11.11 | 10:08 am
- Zacks #1 Rank Additions for Wednesday - Tale of the Tape - Zacks 08.10.11 | 09:08 am
- Zacks #1 Rank Additions for Thursday - Tale of the Tape - Zacks 07.21.11 | 09:07 am
- Adventrx Pharmaceuticals: Undervalued Based on Product Approval Potential - Seeking Alpha 07.21.11 | 08:07 am
- Upcoming PDUFA Dates for Sub-$5 Stocks - Seeking Alpha 07.05.11 | 09:07 am
